Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
In a direct-to-patient move likely to reverberate across the pharmaceutical landscape, Bristol-Myers Squibb and Pfizer announced today they will begin offering their blockbuster blood thinner Eliquis ...
Bristol Myers Squibb and Pfizer are offering an insurance-free pathway to access one of their widely used blood thinners. The pharmaceutical giants launched a new direct-to-patient option for ...
Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback